×
About 2,105 results

ALLMedicine™ Hypoparathyroidism Center

Research & Reviews  704 results

Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: ...
https://doi.org/10.1089/thy.2021.0179
Thyroid : Official Journal of the American Thyroid Associ... Dekker BL, Muller Kobold AC et. al.

Sep 14th, 2021 - Survivors of pediatric differentiated thyroid carcinoma (DTC) receive thyrotropin (TSH) suppressive therapy to minimize disease recurrence. However, knowledge about long-term effects of subclinical hyperthyroidism on bone mineral density (BMD) in ...

Hypoparathyroidism associated with vascular centrum semiovale calcifications.
https://doi.org/10.1002/ana.26210
Annals of Neurology; Trandafir C, Renard D

Sep 10th, 2021 - Hypoparathyroidism associated with vascular centrum semiovale calcifications.|2021|Trandafir C,Renard D,|

Role of the 2018 American Thyroid Association statement on postoperative hypoparathyroi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414735
BMC Surgery; Qiu Y, Xing Z et. al.

Sep 4th, 2021 - Definitions of postoperative hypoparathyroidism (hypoPT) have never reached consent until the American Thyroid Association (ATA) statement was released, with new characteristics and challenges. Patients with papillary thyroid carcinoma who underwe...

PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence from P...
https://doi.org/10.1002/jbmr.4429
Journal of Bone and Mineral Research : the Official Journ... Ovejero D, Hartley IR et. al.

Sep 1st, 2021 - Parathormone (PTH) and fibroblast growth factor 23 (FGF23) both influence blood phosphate levels by regulating urinary phosphate reabsorption. Clinical data suggest that adequate renal phosphate handling requires the presence of both FGF23 and PTH...

see more →

Guidelines  5 results

Management of immune-related adverse events in endocrine organs induced by immune check...
https://doi.org/10.1507/endocrj.EJ19-0163
Endocrine Journal; Arima H, Iwama S et. al.

Jun 28th, 2019 - Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve,...

American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, ...
https://doi.org/10.1089/thy.2017.0309
Thyroid : Official Journal of the American Thyroid Associ... Orloff LA, Wiseman SM et. al.

Jun 1st, 2018 - Hypoparathyroidism (hypoPT) is the most common complication following bilateral thyroid operations. Thyroid surgeons must employ strategies for minimizing and preventing post-thyroidectomy hypoPT. The objective of this American Thyroid Association...

Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian ...
https://doi.org/10.20945/2359-3997000000015
Archives of Endocrinology and Metabolism; Maeda SS, Moreira CA et. al.

Apr 26th, 2018 - Objective To present an update on the diagnosis and treatment of hypoparathyroidism based on the most recent scientific evidence. Materials and methods The Department of Bone and Mineral Metabolism of the Sociedade Brasileira de Endocrinologia e M...

European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyr...
https://doi.org/10.1530/EJE-15-0628
European Journal of Endocrinology; Bollerslev J, Rejnmark L et. al.

Jul 15th, 2015 - Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease with low calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment is activated vit...

American Thyroid Association statement on optimal surgical management of goiter.
https://doi.org/10.1089/thy.2013.0291
Thyroid : Official Journal of the American Thyroid Associ... Chen AY, Bernet VJ et. al.

Dec 4th, 2013 - Goiter, or benign enlargement of the thyroid gland, can be asymptomatic or can cause compression of surrounding structures such as the esophagus and/or trachea. The options for medical treatment of euthyroid goiter are short-lived and are limited ...

see more →

Drugs  62 results see all →

Clinicaltrials.gov  3 results

Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection
https://clinicaltrials.gov/ct2/show/NCT04339478

Aug 26th, 2021 - Real-time intraoperative identification and functional maintenance of structures are of major importance in endocrine surgery, with a critical role in clinical outcomes and patients' quality of life. Despite the advances in preoperative imaging te...

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
https://clinicaltrials.gov/ct2/show/NCT01268098

Jun 11th, 2021 - Patients with a history of Hypoparathyroidism will be randomized to receive study drug for 8 weeks, which will be injected daily in either thigh. During that time they will be monitored for safety (specifically calcium levels in blood or urine). I...

Subtotal Versus Total Thyroidectomy for Benign Goiter
https://clinicaltrials.gov/ct2/show/NCT01273714

Jan 10th, 2011 - The extent of thyroid resection in bilateral multinodular non-toxic goiter remains controversial. Surgeons still continue to debate whether the potential benefits of total thyroidectomy outweigh the potential complications. Most low-volume surgeon...

see more →

News  67 results

Natpar(a): A Case in Point for Rare Disease Drugs?
https://www.medscape.com/viewarticle/922834

Dec 18th, 2019 - While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the situation for patients with chronic hypoparathyroidism who want to take the drug in Europe (where it'...

Natpar(a): A Case in Point for Rare Disease Drugs?
https://www.staging.medscape.com/viewarticle/922834

Dec 18th, 2019 - While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the situation for patients with chronic hypoparathyroidism who want to take the drug in Europe (where it'...

Drug Recall in US Causes Hypoparathyroid Patients Extreme Hardship
https://www.medscape.com/viewarticle/921971

Dec 2nd, 2019 - The recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States over safety concerns about the product is gravely affecting the lives of American patients with severe hypoparathyroidism who need replacement PT...

A Lesson From the Instant Pot: How About a Troubleshooting Guide for Patients?
https://www.medscape.com/viewarticle/921594

Nov 27th, 2019 - Last year, during the post-Thanksgiving Day sales, an Instant Pot I'd had my eye on became available at a bargain price. So I got one, took it home, and read the instruction manual so as to not violate the Gay-Lussac law of the mass, pressure, and...

Parathyroid Hormone Replacement Effective, Safe Long Term
https://www.medscape.com/viewarticle/911357

Apr 4th, 2019 - NEW ORLEANS — Recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) (Natpara, Shire) was safe and effective over 6 years of continuous use for the treatment of adults with chronic hypoparathyroidism, new research shows. Findings from the long-t...

see more →

Patient Education  1 results see all →